ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK-Abelló A/S held its Annual General Meeting on 18 March 2021.
The Annual General Meeting transacted the following business:
- Adoption of the annual report 2020 and discharge of the Board of Directors and Board of Management
- No declaration of ordinary dividend
- Adoption of the remuneration report for 2020
- Adoption of the remuneration to the Board of Directors for the present year
- Re-election of Anders Hedegaard as the Chairman of the Board of Directors
- Re-election of Lene Skole as the Vice Chairman of the Board of Directors
- Re-election of Lars Holmqvist, Jakob Riis and Vincent Warnery as well as new election of Gitte Aabo and Bertil Lindmark to the Board of Directors
- Re-appointment of PwC Statsautoriseret Revisionspartnerselskab as the company’s auditor
- Adoption of the following proposals from the Board of Directors:
- Authorisation for the Board to hold fully electronic general meetings
- Preparation etc. of corporate announcements and documents for internal use by the general meeting in English
- Indemnification of the Board of Directors and Board of Management
- Update of the remuneration policy
- Authorisation for the Board to hold fully electronic general meetings
ALK-Abelló A/S
For further information please contact:
Anders Hedegaard, Chairman, tel. +45 4574 7576
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
NTR Holding A/S9.1.2026 09:37:54 CET | Press release
Nasdaq Copenhagen A/S godkender afnotering af NTR Holding A/S’ B-aktier
Alveus Therapeutics Inc9.1.2026 09:13:19 CET | Pressemeddelelse
Alveus Therapeutics annoncerer serie A-financiering på 160 mio. USD til næste generations behandlinger mod fedme og stofskiftesygdomme
Yacht Club de Monaco9.1.2026 09:05:00 CET | Press release
At the Yacht Club de Monaco a year of transition and innovation begins
Onco3R Therapeutics BV9.1.2026 09:00:00 CET | Press release
O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated
Zealand Pharma9.1.2026 08:00:00 CET | Press release
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
